The role of peroxisome proliferator-activated receptors in healthy and diseased eyes

Keyphrases

• Peroxisome Proliferator-activated Receptor 100%
• Receptor Activation 9%
• Receptor Antagonist 4%
• Glaucoma 4%
• Neuroprotection 4%
• Energy Homeostasis 4%
• Diabetes 4%
• Ocular Diseases 4%
• Retina 4%
• Novel Therapeutics 4%
• Therapeutic Implications 4%
• Adverse Effects 4%
• Lipid Levels 4%
• Neovascularization 4%
• Inflammation 4%
• Age-related Macular Degeneration 4%
• Eye Diseases 4%
• Therapeutic Potential 4%
• Homeostasis 4%
• Cell Differentiation 4%
• Ligand-receptor Binding 4%
• Cornea 4%
• Nuclear Receptor 4%
• Receptor Mechanisms 4%
• Ocular Pathology 4%
• Non-alcoholic Fatty Liver Disease (NAFLD) 4%
• Adipogenesis 4%
• Dry Eye 4%
• Peroxisome Proliferator-activated Receptor Agonists 4%
• Receptor Isoforms 4%
• Ocular Neuropathy 4%
• Functional Properties 4%
• Cell Metabolism 4%
• Lipolysis 4%
• Cell Inflammation 4%
• Fatty Acid Metabolism 4%
• PPARD 4%
• Isoform Function 4%
• Synthetic Ligands 4%
• Diabetic Eye Disease 4%

Medicine and Dentistry

• Peroxisome Proliferator Activated Receptor 100%
• Eye Disease 16%
• Homeostasis 11%
• Peroxisome Proliferator Activated Receptor Delta 11%
• Disease 5%
• Diabetes 5%
• Diabetes Mellitus 5%
• Glaucoma 5%
• Atherosclerosis 5%
• Neuroprotection 5%
• Adverse Event 5%
• Age Related Macular Degeneration 5%
• Neuropathy 5%
• Cell Differentiation 5%
• Nonalcoholic Fatty Liver 5%
• Ocular Pathology 5%
• Cell Metabolism 5%
• Adipogenesis 5%
• Dry Eye 5%
• Peroxisome Proliferator Activated Receptor Agonist 5%
• Cell Nucleus Receptor 5%
• Fatty Acid Metabolism 5%
• Peroxisome Proliferator Activated Receptor Alpha 5%
• Peroxisome Proliferator Activated Receptor Antagonist 5%
• Receptor Mechanism 5%
• Lipolysis 5%
• Peroxisome Proliferator Activated Receptor Gamma 5%

Pharmacology, Toxicology and Pharmaceutical Science

• Peroxisome Proliferator Activated Receptor 100%
• Eye Disease 16%
• Inflammation 11%
• Peroxisome Proliferator Activated Receptor Delta 11%
• Glaucoma 5%
• Neuroprotection 5%
• Adverse Event 5%
• Diabetes Mellitus 5%
• Atherosclerosis 5%
• Disease 5%
• Age Related Macular Degeneration 5%
• Neovascularization (Pathology) 5%
• Fatty Acid 5%
• Neuropathy 5%
• Nonalcoholic Fatty Liver 5%
• Dry Eye 5%
• Peroxisome Proliferator Activated Receptor Gamma 5%
• PPAR Agonist 5%
• Cell Nucleus Receptor 5%
• Peroxisome Proliferator Activated Receptor Alpha 5%
• Peroxisome Proliferator Activated Receptor Antagonist 5%